Collective Accuryn Physiologic Signals and Signatures (CAPSS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03817281|
Recruitment Status : Withdrawn (Lack of Enrollment)
First Posted : January 25, 2019
Last Update Posted : January 13, 2021
|Condition or disease||Intervention/treatment|
|Critical Illness Acute Kidney Injury Sepsis Septic Shock Abdominal Compartment Syndrome||Device: Accuryn Monitoring System|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||0 participants|
|Target Follow-Up Duration:||30 Days|
|Official Title:||Collective Accuryn Physiologic Signals and Signatures: A Retrospective and Prospective Analysis (CAPSS Study)|
|Actual Study Start Date :||March 29, 2020|
|Actual Primary Completion Date :||March 29, 2020|
|Actual Study Completion Date :||March 29, 2020|
Accuryn Monitoring System
Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
Device: Accuryn Monitoring System
The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
- Physiologic Changes [ Time Frame: 30 days ]Track and analyze changes in physiologic data streams captured using the Accuryn Monitoring System to identify clinical signatures that may enable earlier diagnosis and effective intervention of critical conditions. Potential examples include AKI, sepsis/septic shock, ACS, and optimization of fluid resuscitation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03817281
|United States, Washington|
|University of Washington Harborview Medical Center|
|Seattle, Washington, United States, 98104|
|Principal Investigator:||Eileen M Bulger, MD||University of Washington Harborview|